Fluvastatin acid

Base Information

• Chemical Name: Fluvastatin acid
• CAS No.: 93957-54-1
• Molecular Formula: C24H26FNO4
• Molecular Weight: 411.473
• European Community (EC) Number: 695-664-7
• Nikkaji Number: J2.058.624I
• Wikipedia: Fluvastatin
• ChEMBL ID: CHEMBL1625726
• Mol file: 93957-54-1.mol

Synonyms:Fluvastatin acid;CHEMBL1625726;FJLGEFLZQAZZCD-DBBWNDPISA-N;93957-54-1;A844749;(3R,5S,6E)-3,5-Dihydroxy-7-[3-(4-fluorophenyl)-1-isopropyl-1H-indol-2-yl]-6-heptenoic acid

Chemical Property of Fluvastatin acid

Chemical Property:

• Appearance/Colour: Solid
• Vapor Pressure: 1.6E-19mmHg at 25°C
• Melting Point: 194-197oC
• Boiling Point: 681.782 °C at 760 mmHg
• PKA: 4.27±0.10(Predicted)
• Flash Point: 366.128 °C
• PSA: 82.69000
• Density: 1.231 g/cm³
• LogP: 4.62810
• Storage Temp.: 2-8°C
• XLogP3: 3.5
• Hydrogen Bond Donor Count: 3
• Hydrogen Bond Acceptor Count: 5
• Rotatable Bond Count: 8
• Exact Mass: 411.18458647
• Heavy Atom Count: 30
• Complexity: 590

Purity/Quality:

99% ^*data from raw suppliers

Fluvastatin ^*data from reagent suppliers

Safty Information:

• Pictogram(s): Xi
• Hazard Codes: Xi

MSDS Files:

SDS file from LookChem

Useful:

• Canonical SMILES: CC(C)N1C2=CC=CC=C2C(=C1C=CC(CC(CC(=O)O)O)O)C3=CC=C(C=C3)F
• Isomeric SMILES: CC(C)N1C2=CC=CC=C2C(=C1/C=C\[C@H](C[C@H](CC(=O)O)O)O)C3=CC=C(C=C3)F
• Uses: A synthetic HMG-CoA reductase inhibitor
• Therapeutic Function: Antihyperlipidemic
• Clinical Use: HMG CoA reductase inhibitor:Primary hypercholesterolaemiaSlowing progression of atherosclerosisSecondary prevention of coronary events after percutaneous coronary intervention
• Drug interactions: Potentially hazardous interactions with other drugs Antibacterials: rifampicin increases metabolism; increased risk of myopathy with daptomycin; avoid for 7 days after last dose of fusidic acid. Anticoagulants: anticoagulant effect enhanced. Antiepileptics: concentration of either or both drugs may be increased with fosphenytoin and phenytoin. Antifungals: concentration increased by fluconazole - increased risk of myopathy. Antivirals: possible increased risk of myopathy with ledipasvir - reduce fluvastatin dose; avoid with paritaprevir. Ciclosporin: concomitant treatment with ciclosporin may lead to risk of muscle toxicity. Colchicine: isolated cases of myopathy have been reported. Lipid-lowering drugs: increased risk of myopathy with gemfibrozil, fibrates and nicotinic acid - avoid with gemfibrozil.

Technology Process of Fluvastatin acid

There total 2 articles about Fluvastatin acid which guide to synthetic route it. The literature collected by LookChem mainly comes from the sharing of users and the free literature resources found by Internet computing technology. We keep the original model of the professional version of literature to make it easier and faster for users to retrieve and use. At the same time, we analyze and calculate the most feasible synthesis route with the highest yield for your reference as below:

synthetic route:

Reference yield:

fluvastatin sodium (94061-80-0) → fluvastatin (93957-54-1,155229-75-7)

Guidance literature:

With sodium hydrogen sulfate; In water; ethyl acetate;

Reference yield:

→ fluvastatin (93957-54-1,155229-75-7)

Guidance literature:

Reference yield: 91.3%

berberine chloride (633-65-8) + fluvastatin (93957-54-1,155229-75-7) → C20H18NO4(1+)*C24H25FNO4(1-)

Guidance literature:

With sodium hydroxide; In ethanol; water; at 60 - 70 ℃; pH=7 - 8; Concentration;

upstream raw materials:

fluvastatin sodium

Downstream raw materials:

Fluvastatin lactone

Refernces

• 1、 -. "COMPOSITIONS AND TREATMENTS FOR INHIBITING KINASE AND/OR HMG-COA REDUCTASE". Page/Page column 53. . Retrieved 2008/06/13.
• 2、 -. "Method for producing pharmaceutical dosage forms". . . Retrieved 2008/06/13.